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The purpose of this phase II randomised trial was to determine which of two schemes, raltitrexed-irinotecan or raltitrexed-oxaliplatin,
offered better activity and less toxicity in patients with advanced colorectal cancer (CRC). A total of 94 patients with previously
untreated metastatic CRC were included and randomised to receive raltitrexed 3mgm
 2 followed by oxaliplatin 130mgm
 2 on day
1 (arm A), or CPT-11 350mgm
 2 followed by raltitrexed 3mgm
 2 (arm B). In both arms treatment was repeated every 3 weeks.
Intent-to-treat (ITT) analysis showed an overall response rate of 46% (95% CI, 29.5–57.7%) for arm A, and 34% (95% CI, 19.8–
48.4%) for arm B. Median time to progression was 8.2 months for arm A and 8.8 months for arm B. After a median follow-up of 14
months, 69% of patients included in arm A were still alive, compared to 59% of those included in arm B. Overall, 31 patients (65%)
experienced some episode of toxicity in arm A and 32 patients (70%) in arm B, usually grade 1–2. The most common toxicity was
hepatic, with 29 patients (60%) in arm A and 24 patients (62%) in arm B, and was grade 3–4 in four (8%) and four (9%) patients,
respectively. In all, 14 patients (29%) from arm A and 24 patients (52%) from arm B had some grade of diarrhoea (Po0.03).
Neurologic toxicity was observed in 31 patients (64%) in arm A, and was grade 3–4 in five patients (10%), while a cholinergic
syndrome was detected in nine patients (19%) in arm B. There were no differences in haematologic toxicity. One toxic death (2%)
occurred in arm A and three (6.5%) in arm B. In conclusion, both schemes have high efficacy as first-line treatment in metastatic CRC
and their total toxicity levels are similar. Regimens with raltitrexed seem a reasonable alternative to fluoropyrimidines.
British Journal of Cancer (2005) 93, 1230–1235. doi:10.1038/sj.bjc.6602860 www.bjcancer.com
Published online 1 November 2005
& 2005 Cancer Research UK
Keywords: colorectal cancer; raltitrexed; oxaliplatin; irinotecan; toxicity
                                                              
For more than 40 years, 5-fluorouracil (5FU) was the only
cytotoxic agent with significant activity in advanced colorectal
cancer (CRC). Recently, however, the topoisomerase I inhibitor
irinotecan (CPT-11) and the platinum compound oxaliplatin have
shown efficacy as second-line single-agent therapy and as first-line
therapy in combination with fluoropyrimidines. In large phase III
trials, irinotecan in combination with 5FU/leucovorin (LV) and
oxaliplatin in combination with 5FU/LV showed superior efficacy
compared with 5FU/LV alone as first-line therapy (Douillard et al,
2000; Giacchetti et al, 2000; de Gramont et al, 2000; Saltz et al,
2000; Grothey et al, 2002).
Although combined therapy has been an important develop-
ment in the treatment of advanced CRC, these regimens do have
some disadvantages. Firstly, their increased toxicity, particularly
with the CPT-11–5FU–LV combination when 5FU is administered
by bolus (Ledermann et al, 2001; Rothenberg et al, 2001).
Secondly, continuous-infusion-based regimens require the
use of implantable access devices and portable infusion pump,
which is associated with an increased risk of infection and
thromboembolism (Clark and Raffin, 1990; Prandoni and
Bernardi, 1999; Verso and Agnelli, 2003). Thirdly, the inconve-
nience and discomfort of regular hospital visits for intravenous
(i.v.) drug administration, which can have a negative effect on
their quality of life.
Raltitrexed is a specific inhibitor of thymidylate synthase. This
enzyme has a fundamental role in the de novo synthesis of the
nucleotide thymidine triphosphate, which is essential for DNA
synthesis. At a dose of 3mgm
 2, it is active in a variety of tumours
such as breast, pancreatic or refractory ovarian cancers (Cunning-
ham et al, 1994), but it is in colorectal tumours where it shows the
highest activity (Van Custem et al, 2002). Several phase III studies
performed in patients with advanced CRC demonstrated that
response rates and survival were similar to that of the combination
5FU–LV (Cunningham et al, 1995; Cocconi et al, 1998; Maughan
et al, 2002). However, in another randomised trial, a survival
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sadvantage in favour of patients treated with conventional 5FU–LV
was seen even when the response rate was similar (Pazdur and
Vicent, 1997).
Administration as a short 15-min i.v. infusion every 3 weeks
adds value to the efficacy and toxicity profile of raltitrexed. In fact,
in a study which compared the patients’ preferences between
raltitrexed and other 5FU-based regimens with regard to side-
effects and administration attributes, 91% of the patients expressed
a preference for the former treatment (Young et al, 1999).
Several studies have shown a sequence-specific synergistic
cytotoxicity for the combination of raltitrexed with CPT-11
(Aschele et al, 1988), while for the combination of raltitrexed
with oxaliplatin both synergistic and additive antineoplastic
activities have been observed (Raymond et al, 1997).
Several phase II studies with the raltitrexed–CPT-11 combina-
tion have shown response rates of 34–46% (Carnaghi et al, 2002;
Feliu et al, 2004) and median survivals of 12–15.6 months. On the
other hand, with the raltitrexed–oxaliplatin combination, response
rates of 41–54% and median survivals of 14.6–14.8 months have
been reported (Cascinu et al, 2002; Seitz et al, 2002; Santini et al,
2004). These results are comparable to those achieved with 5FU–
LV combinations with CPT-11 or oxaliplatin.
In view of these encouraging clinical data and the continuing
need for active regimens with an alternative mechanism of
action other than 5FU–LV, evaluation of the therapeutic
potential of the combination of raltitrexed with CPT-11 or
oxaliplatin seems to be of considerable interest. We thus decided
to initiate a randomised phase II study in previously untreated
patients with advanced CRC to determine which of two schemes,
raltitrexed–CPT-11 or raltitrexed–oxaliplatin, offered higher
activity and less toxicity, with a view to their selection for a
subsequent phase III trial which would compare this regimen with
a control arm treated with a regimen of 5FU–LV and CPT-11 or
oxaliplatin.
PATIENTS AND METHODS
Patient population
A total of 94 patients with recurrent or metastatic CRC were
included from May 2002 to December 2003. They all had at least
one lesion histologically confirmed adenocarcinoma. Patients who
had received prior adjuvant 5FU-based chemotherapy were eligible
if they had remained free of disease for at least 6 months after
completion of the adjuvant therapy. Patients with operable
metastatic disease were excluded from the study. Other inclusion
criteria were: (1) a performance status p2, according to the
Eastern Cooperative Oncology Group (ECOG) scale; (2) life
expectancy of at least 3 months; (3) adequate bone marrow
function, that is, a granulocyte count X2 10
9l
 1 and platelets
4100 10
9l
 1; (4) peripheral neuropathy (pgrade 1, National
Cancer Institute Common Toxicity Criteria (NCI-CTC) scale); (5)
adequate hepatic function, that is, serum bilirubin o1.25 times the
upper normal limit, glutamic oxaloacetic transaminase values
(SGOT) and glutamic pyruvic transaminases (SGPT) o2.5 times
the upper normal limit in the absence of hepatic metastases or o5
times the upper normal limit in the presence of metastasis; (6)
adequate renal function, that is, a creatinine value p1.25 times the
upper normal limit and creatinine clearance 465mlmin
 1.
Patients with any prior chemotherapy for advanced disease,
brain or meningeal metastases, or a history of any other
malignancy, were excluded, except in cases of basal cell carcinoma
or in situ cervical carcinoma adequately treated. Patients provided
written informed consent according to the directives of the local
ethical committees.
All patients had measurable disease, as defined by the
presence of at least one unidimensionally measurable lesion by
computed tomography scan. Pleural effusion, ascites, osteoblastic
lesions or previously irradiated lesions were not accepted as
measurable disease. Patients who had received radiotherapy
were eligible if there was at least one measurable lesion outside
the radiation field.
Treatment plan
Chemotherapy consisted of 3-weekly courses either of raltitrexed
3mgm
 2 as a 15-min i.v. infusion followed 45min later by
oxaliplatin 130mgm
 2 on day 1, given as a 2-h infusion in 250ml
of dextrose 5% (arm A), or 3-weekly courses of CPT-11
350mgm
 2 in a 30-min i.v. infusion followed by a 15-min
infusion of raltitrexed 3mgm
 2 (arm B). Antiemetic and
symptomatic therapies were permitted, with the exception of any
vitamin supplement containing folic acid. Patients were to be
withdrawn from the study as a result of any of the following: (1)
objective disease progression (according to protocol criteria); (2)
unacceptable toxicity or adverse event; (3) patient unwilling or
unable to continue (dropouts); (4) patient lost to follow-up; (5)
investigator decision that it was in the patient’s best interest not to
continue.
Patients were assessed for toxicity before each course and
graded according to NCI-CTC version 2. Therapy was delayed for 1
week if the neutrophil count was o1.5 10
9l
 1 or the platelet
count o100 10
9l
 1, or for significantly persisting nonhaemato-
logical toxicity. Therapy was definitely discontinued if toxicity
persisted after a 2-week delay. In case of grade 3 or 4
haematological toxicity, the dose of all drugs was decreased by
25 or 50%, respectively. If grade 2 or 3 diarrhoea or stomatitis
occurred, the dose was reduced by 25 or 50%, respectively; grade 4
diarrhoea or stomatitis led to treatment withdrawal. The
oxaliplatin dose was reduced by 25% for subsequent cycles in
case of persistent (X14 days) or temporary (7–14 days) painful
paresthesia or functional impairment. In case of persistent painful
paresthesia or functional impairment, or if a patient experienced
any other severe neurotoxicity despite a 25% dose attenuation,
oxaliplatin was omitted in subsequent cycles. In case of the
occurrence of a laryngeal spasm syndrome, the duration of the
oxaliplatin infusion was increased from 2 to 6h. In case of
persistent problems, oxaliplatin was omitted. The Cockcroft–Gault
formula (Cockcroft and Gault, 1976) was used to calculate
creatinine clearance before each cycle. If creatinine clearance was
between 55 and 65mlmin
 1, the dose of raltitrexed was reduced by
25% and the next cycle given 4 weeks later. If it was between 25
and 54mlmin
 1 the dose of raltitrexed was reduced by 50% and
the next cycle given 4 weeks later, and if it was o25mlmin
 1 the
treatment was interrupted.
Pretreatment and followup studies
A diagnostic workup was performed within 3 weeks prior to the
start of treatment, consisting of a complete clinical history,
physical examination, performance status assessment, haematolo-
gical and biochemical profiles (including CEA level), a chest X-ray
and a computed tomography scan of the chest and abdomen at
baseline. Additional imaging investigations were performed if
clinically indicated. A computed tomography scan was repeated
every three courses to assess the objective response. At the end of
chemotherapy, all clinical, laboratory and imaging studies were
repeated and patients underwent followup examination every 2 or
3 months until death.
Response criteria
Patients were evaluated clinically on an ITT basis at least every 3
weeks and radiographically every 9 weeks. The same evaluation
modality was used throughout the study. RECIST response
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sguidelines were used (Therasse et al, 2000), defining all responses
after at least 9 weeks of therapy as follows: complete response
(CR), partial response (PR), stable disease (SD) or progressive
disease (PD). We defined disease control as the sum of patients
achieving a CR, PR or SD. Confirmation of all responses was
required after 4 weeks. Duration of response was defined as the
period from the first day the criteria for CR or PR were met to the
progression date. Time to tumour progression (TTP) was
estimated from the dates of the first course of treatment to the
first documentation of disease progression. Survival was calculated
by the same method from the date of the first cycle of treatment
until the date of death or last known followup.
Statistical analysis
The primary end point was response rate and the secondary
objectives time to progression and toxicity. Dose intensity was
calculated by dividing the total mgm
 2 of drug given by the
number of weeks elapsed from the beginning of therapy to the end
of the last cycle.
The ‘pick the winner’ format based on the randomised phase II
clinical trials approach as proposed by Simon et al (1985) was
used. In this approach, an accrual of 38 patients in each arm gives
a 90% chance of selecting the better treatment schedule if the
difference in response rate is at least 15% and the smaller response
rate is assumed to be approximately 35%. Also, 10% was added to
this figure to allow for losses. If both schedules were between the
pre-established ranges of response rate, the less toxic regimen
would be chosen.
The Wilcoxon rank-sum method was used to compare
quantitative variables, the Fisher’s exact test for percentages, and
the Kaplan–Meier method for survival, TTP and the duration of
response.
RESULTS
Patient characteristics
A total of 94 patients with recurrent or metastatic CRC were
entered into the study and received the allocated treatment
subsequent to randomisation. In all, 48 patients were randomised
to arm A (oxaliplatin/raltitrexed) and 46 to arm B (irinotecan/
raltitrexed). As shown in Table 1, the two groups were well
matched for pretreatment characteristics. The patients’ median age
was 64 years, and the majority (95%) had an ECOG performance
status of 0 or 1. The primary tumour was located in the colon in 58
(62%) and in the rectum in 36 (38%). Synchronous metastatic
disease was observed in 48 patients (51%), in 22 of which (23%)
the primary tumour was not resected. Of the remaining patients,
46 (50%) presented metastases secondary to a tumour previously
removed. Of these patients, 31 (33%) had previously received
adjuvant chemotherapy and 11 (12%) had received chemotherapy
and radiotherapy. The liver was the predominant metastatic site
(68%), and the median number of involved sites was two per
patient.
Seven patients were unassessable for treatment efficacy, four in
arm A (one because of severe toxicity, one due to toxic death, one
moved to a different city and one due to death apparently
unrelated to the neoplasia, i.e., acute myocardial infarction) and
three in arm B (two due to toxic death and one because of severe
toxicity). These patients were retained for the ITT analysis.
Dose intensities
Patients in arm A (oxaliplatin/raltitrexed) received a total of 303
cycles, with a median of six cycles per patient (range 1–16).
Patients in arm B (irinotecan/raltitrexed) received 286 cycles, with
a median of six cycles per patient (range 1–23). In seven patients
Table 1 Patients’ characteristics
Oxaliplatin/raltitrexed Irinotecan/raltitrexed
Characteristic No. % No. %
Age (mean and range) 63 (37–74) 65 (36–76)
Sex
Male 28 58 31 67
Female 20 42 15 33
ECOG performance status
02 6 5 4 2 3 5 0
11 8 3 8 2 2 4 8
24 8 1 2
Primary site
Colon 32 67 26 57
Rectum 16 33 20 43
Metastasis sites
Liver 34 71 30 65
Lung 9 18 16 35
Abdominopelvic mass 18 37 13 28
Others 12 25 18 39
No of metastatic sites
Single 19 40 17 37
Multiple 29 60 29 63
Prior adjuvant therapy
None 27 56 24 52
Chemotherapy 14 29 17 37
Chemotherapy+radiotherapy 7 15 5 11
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s(15%) from arm A and eight (17%) from arm B a delay occurred in
administration of the treatment. In arm A the reasons for the delay
were: elevation of transaminases in four, diarrhoea in two and
thrombopenia in one, and in arm B elevation of transaminases in
four, diarrhoea in two and neutropenia in two. In arm A, the
median dose intensity was 41mgm
 2week
 1 for oxaliplatin and
0.95mgm
 2week
 1 for raltitrexed. These doses represent 95% of
the scheduled doses both for oxaliplatin and raltitrexed. In arm B,
the median dose intensity was 114mgm
 2week
 1 for irinotecan
and 0.97mgm
 2week
 1 for raltitrexed. These doses represent 98%
of the scheduled dose for irinotecan and 97% of the scheduled dose
for raltitrexed.
Tumour response and survival
The data for response, progression-free survival and overall
survival are shown in Table 2. Assessment of response was by
ITT on the total population included (48 patients in arm A and 46
in arm B) and per protocol on the patients who received three or
more treatment cycles and were fully assessable for response (46 in
arm A and 43 in arm B). According to the ITT analysis, the overall
response rate was 46% (95% CI 29.5–57.7%) for arm A
(oxaliplatin/raltitrexed) and 34% (95% CI, 19.8–48.4%) for arm
B (irinotecan/raltitrexed). These differences were not significant
(P40.05). In the per protocol analysis, the overall response rates
were 49% (95% CI, 33.3–62.9%) and 37% (95% CI, 21.2–51.3%)
(P40.05), respectively. Median duration of response was 7.9 and
9.2 months, respectively (P¼0.696, log-rank test). Overall, control
of disease (CRþPRþSD) was achieved in 35 patients (69%) in
arm A and in 31 patients (67%) in arm B.
At the time of performing the analysis, 37 patients (77%) in arm
A and 34 patients (74%) in arm B had progressed. The median TTP
was 8.2 months for arm A and 8.8 months for arm B (P¼0.565,
log-rank test). After a median follow-up of 14 months, 69% of the
patients included in arm A were still alive, compared to 59% of
those included in arm B, and therefore median survival could not
be calculated.
Second-line chemotherapy with irinotecan was administered to
24 (65%) of 37 patients who progressed in arm A and second-line
treatment with oxaliplatin to 21 (68%) patients who progressed in
arm B.
Toxicity
Overall, 31 patients (65%) experienced some toxicity in arm A and
32 patients (70%) in arm B, usually grade 1–2. The main toxicities
were gastrointestinal and haematologic. Treatment-related side
effects are shown in Table 3. In general, both regimens were well-
tolerated. The most common toxicity was hepatic, with elevation of
transaminases being detected in 29 patients (60%) in arm A and 24
patients (62%) in arm B, although grade 3–4 toxicity was only
observed in four (8%) and four (9%) of patients, respectively. It
should be noted that 14 patients (31%) from arm A had some
grade of diarrhoea, while it was observed in 24 patients (52%) from
arm B (Po0.05). These differences can be attributed to a higher
frequency of grade 1–2 diarrhoea in arm B (23 vs 39%). However,
Table 2 Therapeutic results
Oxaliplatin/raltitrexed Irinotecan/raltitrexed
Results No. % No. %
Complete response 4 8 2 4
Partial response 18 38 14 30
Stable disease 12 25 15 33
Progressive disease 11 23 12 33
Nonevaluables 3 6 3 7
Overall response rate (%) (95% confidence interval) 46% (29.5–57.7%) 34% (19.8–48.4%)
Response duration (months)
Median 7.9 9.2
Range 5.4–9.5 6.3–10
Progression-free survival (months)
Median 8.2 8.8
Range 5.8–10.4 6.8–10.6
Table 3 Toxicity per patient according to NCI-CTC grade
Oxaliplatin/raltitrexed (n¼48) Irinotecan/raltitrexed (n¼46)
Toxicity Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Neutropenia 3 (6%) 1 (2%) 5 (11%) 4 (8%)
Anaemia 8 (17%) 2 (4%) 11 (24%) 1 (2%)
Thrombocytopenia 4 (8%) 2 (4%) 3 (7%) 2 (4%)
Nausea/vomiting 20 (42%) 6 (12%) 20 (43%) 3 (7%)
Diarrhoea 11 (23%) 4 (8%) 18 (39%) 6 (13%)
Stomatitis 3 (6%) — 3 (7%) 2 (4%)
Transaminases 25 (53%) 4 (8%) 19 (53%) 4 (9%)
Asthenia 15 (31%) 2 (4%) 21 (46%) 3 (7%)
Peripheral neuropathy 26 (54%) 5 (10%) — —
Alopecia 2 (4%) — 13 (28%) 2 (4%)
Cholinergic syndrome — — 9 (19%)
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sthe percentage of patients with grade 3–4 diarrhoea was similar in
both groups: four patients (8%) in arm A and four patients (13%)
in arm B. Another very common toxicity was asthenia, usually
grade 1–2. Overall, asthenia was detected in 17 patients (35%) in
arm A and in 24 patients (52%) in arm B. However, these
differences were not significant from a statistical point of view
(P¼NS). In addition, neurologic toxicity was observed in 31
patients (64%) in arm A, and was grade 3–4 in five patients (10%),
while a cholinergic syndrome was detected in nine patients (19%)
in arm B. One toxic death (2%) occurred in arm A, due to
diarrhoea, mucositis, neutropenia and sepsis, and three (6.5%) in
arm B, two due to diarrhoea, neutropenia and sepsis and one due
to diarrhoea, mucositis and acute renal failure.
DISCUSSION
In recent years, the incorporation of new drugs active against CRC
with different mechanisms of action has considerably expanded
the therapeutic options. However, advanced CRC continues to be
an incurable disease. Therefore, the objectives of treatment should
be to prolong survival and alleviate symptoms, and to improve or
at least maintain the quality of life of the patients. These objectives
should be achieved by administering regimens that have low
toxicity, are convenient and do not require repeated visits to the
hospital by the patient, so as not to worsen the patient’s quality of
life. The primary objective of this phase II randomised trial
was to determine the activity and tolerance of two chemotherapy
schemes in first-line treatment of metastatic CRC, whose main
advantage over bimonthly schemes is to reduce the number of
hospital visits.
The results obtained in the study suggest that both schemes have
similar efficacy, with no differences being detected in either
response rate (46 vs 34%) or TTP (8.2 vs 8.8 months). The response
rates achieved are similar to those reported by other authors, both
with schemes combining raltitrexed with oxaliplatin (39–54%
response rate) (Cascinu et al, 2002; Seitz et al, 2002; Santini et al,
2004; Gra ´valos et al, 2005) and those combining raltitrexed with
irinotecan (34–46%) (Carnaghi et al, 2002; Feliu et al, 2004).
Similarly, these results are comparable to those obtained with
combinations of 5FU–LV with oxaliplatin or irinotecan (Douillard
et al, 2000; Giacchetti et al, 2000; de Gramont et al, 2000; Saltz et al,
2000; Grothey et al, 2002; Tournigand et al, 2004). Although it is
too soon to analyse the effects on survival, there will probably not
be any significant differences, since, as pointed out by several
authors, what is important is to use standard drugs throughout the
disease, regardless of the order in which they are used (Grothey
et al, 2004; Tournigand et al, 2004), and, in our study, 64% of the
patients in the raltitrexed–oxaliplatin arm and 68% of those in the
raltitrexed–irinotecan arm received a second-line treatment.
As expected, the two schemes showed some differences with
regard to toxicity. The raltitrexed–irinotecan scheme was asso-
ciated more frequently with diarrhoea, usually grade 1–2. In
addition, a higher frequency of alopecia and asthenia was
observed, although the latter did not achieve statistical signifi-
cance. On the other hand, the raltitrexed–oxaliplatin scheme
caused neurologic toxicity in 64% of patients, although it was
grade 3–4 in only 10%. However, we should note the frequency of
toxic deaths observed in the study, one in the raltitrexed–
oxaliplatin arm (2%) and three (6.5%) in the raltitrexed–
irinotecan arm, which represents an overall rate of toxic deaths
of 4.1% in the study. These results contrast with our previous
experience with the raltitrexed–irinotecan scheme in a phase II
trial including 91 patients in which we did not observe any toxic
death (Feliu et al, 2004). On the other hand, the toxic death rate
with the bimonthly continuous-infusion regimens of 5FU–LV with
either oxaliplatin or irinotecan is usually o3% (Douillard et al,
2000; Giacchetti et al, 2000; de Gramont et al, 2000; Goldberg et al,
2004; Tournigand et al, 2004). However, in the joint analysis of
three phase III trials comparing raltitrexed monotherapy vs 5FU–
LV, a 3.8% rate of toxic deaths was observed, although 65% of
these deaths can be attributed to a protocol deviation (Zalckberg,
1997). In another more recent study, which also compared
raltitrexed monotherapy with other 5FU–LV schemes, a 6% rate
of toxic deaths was reported in the raltitrexed arm, although in
some cases treatment was administered before the patients had
completely recovered from a previous toxicity (Maughan et al,
2002). In this regard, special attention should be given to the renal
function of the patients before each cycle of raltitrexed to avoid the
occurrence of unexpected toxicities (Jansman et al, 2000; Van
Custem et al, 2002). In fact, the AUC of raltitrexed can double
when creatinine clearance is less than 65mlmin
 1 (Judson et al,
1998). Nevertheless, despite the fact that in our study this aspect
was contemplated in the protocol and it was stressed to
investigators that they should take it into account, these toxic
deaths still occurred. In this regard, it has also been pointed out
that patients with low serum concentrations of folate have a higher
risk of toxicity from raltitrexed (Keller et al, 2001). This would be
due to cells taking up and retaining raltitrexed more avidly. We do
not know to what extent this aspect may have played a role in the
toxicity observed in our patients.
The main advantage of combinations with raltitrexed over
bimonthly schemes is the possibility of reducing the number of
hospital visits. In fact, in a phase II randomised trial comparing
administration of raltitrexed–oxaliplatin with the FOLFOX4
scheme, a 50% reduction was observed in the number of hospital
visits with the raltitrexed regimen (Gra ´valos et al, 2005). Although
this can currently be achieved with schemes combining oral
fluoropyrimidines with oxaliplatin or irinotecan (Cassidy et al,
2004), with these regimens frequent contacts with the treatment
team are required to adjust the dose or temporarily interrupt
treatment in order to avoid excessive toxicity.
Based on the above, although schemes with raltitrexed have
similar efficacy as that observed with 5FU–LV combinations, due
to its unpredictable toxicity and the development of regimens with
oral fluoropyrimidines, interest in raltitrexed has declined
substantially at present. Nevertheless, it could be useful in patients
in whom the use of fluoropyrimidines is contraindicated for any
reason such as ischaemic heart disease. In these situations, due to
its lower toxicity, administration of the combination of ralti-
trexed–oxaliplatin could be considered.
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